- Home
- ARCT vs CVAC Comparison
ARCT vs CVAC Comparison
Compare ARCT & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- CVAC
- Stock Information
- Founded
- ARCT 2013
- CVAC 2000
- Country
- ARCT United States
- CVAC Germany
- Employees
- ARCT N/A
- CVAC N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- CVAC Health Care
- Exchange
- ARCT Nasdaq
- CVAC Nasdaq
- Market Cap
- ARCT 602.7M
- CVAC 643.8M
- IPO Year
- ARCT N/A
- CVAC 2020
- Fundamental
- Price
- ARCT $20.60
- CVAC $2.82
- Analyst Decision
- ARCT Strong Buy
- CVAC Hold
- Analyst Count
- ARCT 7
- CVAC 3
- Target Price
- ARCT $65.00
- CVAC $10.00
- AVG Volume (30 Days)
- ARCT 338.5K
- CVAC 399.6K
- Earning Date
- ARCT 11-12-2024
- CVAC 11-12-2024
- Dividend Yield
- ARCT N/A
- CVAC N/A
- EPS Growth
- ARCT N/A
- CVAC N/A
- EPS
- ARCT N/A
- CVAC N/A
- Revenue
- ARCT $163,866,000.00
- CVAC $70,565,734.00
- Revenue This Year
- ARCT $13.46
- CVAC $105.61
- Revenue Next Year
- ARCT $5.17
- CVAC N/A
- P/E Ratio
- ARCT N/A
- CVAC N/A
- Revenue Growth
- ARCT N/A
- CVAC 75.11
- 52 Week Low
- ARCT $17.52
- CVAC $2.22
- 52 Week High
- ARCT $45.00
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- ARCT 42.91
- CVAC 38.84
- Support Level
- ARCT $20.00
- CVAC $2.79
- Resistance Level
- ARCT $21.86
- CVAC $2.89
- Average True Range (ATR)
- ARCT 1.49
- CVAC 0.11
- MACD
- ARCT -0.35
- CVAC -0.01
- Stochastic Oscillator
- ARCT 18.04
- CVAC 19.44
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.